natgillin/translations-raw huggingface dataset:
Following a single dose of Teysuno, approximately 3.8% to 4.2% of administered tegafur, 65% to 72% of administered gimeracil, and 3.5% to 3.9% of administered oteracil were excreted unchanged in the urine.
Po enkratnem odmerku zdravila Teysuno se je približno 3,8–4,2 % prejetega tegafurja, 65–72 % prejetega gimeracila in 3,5–3,9 % prejetega oteracila v nespremenjeni obliki izločilo z urinom.
Following a single intravenous 150-mg dose of fosaprepitant administered as a 20-minute infusion to healthy volunteers, the mean AUC0-∞ of aprepitant was 35.0 µghr/ml and the mean maximal aprepitant concentration was 4.01 µg/ml.
Po enkratnem 150 mg intravenskem odmerku fosaprepitanta v obliki 20-minutne intravenske infuzije je bila pri zdravih prostovoljcih povprečna vrednost AUC0-∞ aprepitanta 35,0 μgh/ml, povprečna največja koncentracija aprepitanta pa 4,01 μg/ml.
Following a single intravenous dose of 1000 mg in healthy volunteers AUC in skin blister fluid amounted (bound and unbound dalbavancin) to approximately 60 % of the plasma AUC at day 7 post-dose.
Po enkratnem intravenskem odmerku 1000 mg pri zdravih prostovoljcih je AUC v tekočini v kožnih mehurčkih narasla (vezan in nevezan dalbavancin) na približno 60 % AUC v plazmi 7. dan po odmerku.
Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the drug is well distributed into tissues.
Po enkratnem intravenskem odmerku 12,5 mg alogliptina je volumen porazdelitve v končni fazi pri zdravih osebah znašal 417 litrov, kar kaže, da se zdravilo dobro porazdeli v tkiva.
Following a single intravenous dose of [14C]alendronate, approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces.
Po enkratnem intravenskem odmerku [14C]alendronata se je približno 50 % radioaktivnosti izločilo z urinom v 72 urah; v blatu so našli le malo ali nič radioaktivnosti.
Following a single IV administration, the mean volume of distribution was 115  19 mL/kg.
Po enkratnem intravenskem odmerku zdravila je bila vrednost njegovega srednjega porazdelitvenega volumna 115 ± 19 ml/kg.
Following a single oral (10 mg/kg) administration of [14C] radiolabelled bosutinib to lactating Sprague-Dawley rats, radioactivity was readily excreted into breast milk as early as 0.5 hr after dosing.
Po zaužitju enkratnega peroralnega odmerka (10 mg/kg) [14C] radioaktivno označenega bosutiniba pri doječih Sprague-Dawley podganah se je radioaktivnost izločila v materino mleko že v 0,5 ure po odmerku.
Following a single oral administration of 200 mg 14C-simeprevir to healthy subjects, on average 91% of the total radioactivity was recovered in faeces.
Po enkratnem peroralnem odmerku 200 mg s 14C označenega simeprevirja zdravim osebam so povprečno 91% celotne radioaktivnosti prestregli v blatu.
Following a single oral administration of [14C]-pomalidomide (2 mg) to healthy subjects, approximately 73% and 15% of the radioactive dose was eliminated in urine and faeces, respectively, with approximately 2% and 8% of the dosed radiocarbon eliminated as pomalidomide in urine and faeces.
Po enem peroralnem dajanju [14C]-pomalidomida (2 mg) zdravim osebam se je v urinu izločilo približno 73 % in v blatu približno 15 % radioaktivnega odmerka, s približno 2 % odmerjenega radiokarbona kot pomalidomida v seču in 8% kot pomalidomida v blatu.
Following a single oral administration of radioactive ceritinib dose at 750 mg, ceritinib was the main circulating component in human plasma.
Po peroralnem odmerjanju enkratnega odmerka radioaktivno označenega ceritiniba v odmerku 750 mg so v plazmi pri ljudeh našli predvsem ceritinib.
Following a single oral dose of 150 mg migalastat hydrochloride solution, the time to peak plasma concentration was approximately 3 hours.
Čas do najvišje plazemske koncentracije po enkratnem peroralnem odmerku 150 mg raztopine migalastat hidroklorida je bil približno 3 ure.
Following a single oral dose of 2,897 micrograms linaclotide on day 8, after a 7-day course of
Po enem peroralnem odmerku 2.897 mikrogramov na 8. dan po 7-dnevnem ciklu dajanja
Following a single oral dose of 400 mg of radio-labelled thalidomide, the total mean recovery was 93.6% of the administered dose by Day 8.
Po enkratnem peroralnem odmerku 400 mg radioaktivno označenega talidomida so do 8. dne ponovno pridobili celokupno povprečno vrednost 93,6 % danega odmerka.
Following a single oral dose of [14C]-labeled ponatinib, approximately 87% of the radioactive dose is recovered in the faeces and approximately 5% in the urine.
Po enkratnem peroralnem odmerku s [14C] označenega ponatiniba se je približno 87 % radioativnega odmerka pojavilo v blatu in približno 5 % v urinu.
Following a single oral dose of [14C]-labelled ruxolitinib in healthy adult subjects, elimination was predominately through metabolism, with 74% of radioactivity excreted in urine and 22% via faeces.
Pri zdravih odraslih osebah se je po enkratnem peroralnem odmerku s [14C]-označenega ruksolitiniba ta večinoma izločil s pomočjo presnove, pri čemer se je 74 % radioaktivnih snovi izločilo z urinom, 22 % pa z blatom.
Following a single subcutaneous administration of golimumab to healthy subjects or patients with RA, the median time to reach maximum serum concentrations (Tmax) ranged from 2 to 6 days.
Po enkratnem subkutanem injiciranju golimumaba zdravim preiskovancem ali bolnikom z revmatoidnim artritisom je bila mediana vrednost časa do dosega največje serumske koncentracije zdravila (Tmax) od 2 do 6 dni.
Following a single subcutaneous injection of Pegasys 180 micrograms in healthy subjects, serum concentrations of peginterferon alfa-2a are measurable within 3 to 6 hours.
Po enkratni subkutani injekciji 180 mikrogramov zdravila Pegasys pri zdravih prostovoljcih so serumske koncentracije peginterferona alfa-2a lahko merili v 3 do 6 urah.
Following a subcutaneous dose of Preotact, C-terminal fragments make up about 60-90 of the circulating forms of the molecule.
Po podkožnem odmerjanju zdravila Preotact C-terminalni fragmenti predstavljajo 60-90 % krožečih oblik molekule.
Following abortion or miscarriage
Po umetnem ali spontanem splavu
Following absorption from the skin, moxidectin is distributed systemically and is slowly eliminated from the plasma as manifested by detectable moxidectin concentrations in plasma throughout the treatment interval of one month.
Moksidektin deluje sistemsko ter se počasi izloča iz plazme, kar lahko preverimo z merjenjem koncentracije moksidektina v plazmi v času od nanosa do naslednje aplikacije po mesecu dni.
Following absorption, citrate is converted into bicarbonate by the tissues.
Po absorpciji tkiva citrat pretvorijo v bikarbonat.
Following acute single overdoses ranging between 1,000 mg and 12,000 mg, seizures (generalized tonic-clonic seizures, status epilepticus) and cardiac conduction disorders were observed.
Pri akutnih, enkratnih prevelikih odmerkih med 1000 mg in 12000 mg so opazili epileptične napade (generalizirane tonično-klonične napade, status epilepticus) in motnje prevodnosti srca.
Following administration by lumbar puncture, it is recommended that the patient should be instructed to lie flat for one hour.
Svetujemo, naj bolnik po lumbalni punkciji leži še eno uro.
Following administration by lumbar puncture, the patient should be instructed to lie flat for one hour.
Bolniku naročite, da po dajanju zdravila z lumbalno punkcijo leži še eno uro.
Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete (>90 %) within 24 hours.
Po zaužitju rivastigmina, označenega s 14C, je bilo ledvično izločanje hitro, saj se je dejansko ves (> 90 %) izločil v 24 urah.
Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete (>90 %) within 24 hours.
V 24 urah po uporabi 14C-rivastigmina je bilo izločanje skozi ledvice hitro in skoraj popolno (>90 %).
Following administration of 2 mg daily, steady-state geometric mean Cmax, AUC(0-) and predose concentration were 22.2 ng/ml, 370 ng*hr/ml and 12.1 ng/ml, respectively with a low peak:trough ratio (1.8).
Po uporabi 2 mg na dan so bila v stanju dinamičnega ravnovesja geometrična povprečja Cmax 22,2 ng/ml, AUC(0-) 370 ng*hr/ml in koncentracije pred odmerkom 12,1 ng/ml; razmerje med najvišjo in najnižjo vrednostjo je bilo nizko (1,8).
Following administration of 5 mg/kg infliximab every 8 weeks, the predicted median steady-state infliximab exposure (area under concentration-time curve at steady state, AUCss) in paediatric patients aged 6 years to 17 years was approximately 20% lower than the predicted median steady- state drug exposure in adults.
Pri uporabi infliksimaba 5 mg/kg vsakih 8 tednov je bila napovedana mediana izpostavljenosti infliksimabu v stanju dinamičnega ravnovesja (površina pod krivuljo koncentracija-čas v stanju dinamičnega ravnovesja, AUCss) pri pediatričnih bolnikih, starih od 6 let do 17 let, približno 20 % nižja od napovedane mediane izpostavljenosti zdravilu v stanju dinamičnega ravnovesja pri odraslih.
Following administration of 5 mg/kg infliximab every 8 weeks, the predicted median steady-state infliximab exposure (area under concentration-time curve at steady state, AUCss) in paediatric patients aged 6 years to 17 years was approximately 20% lower than the predicted median steady-state drug exposure in adults.
Pri uporabi infliksimaba 5 mg/kg vsakih 8 tednov je bila napovedana mediana izpostavljenosti infliksimabu v stanju dinamičnega ravnovesja (površina pod krivuljo koncentracija-čas v stanju dinamičnega ravnovesja, AUCss) pri pediatričnih bolnikih, starih od 6 let do 17 let, približno 20 % nižja od napovedane mediane izpostavljenosti zdravilu v stanju dinamičnega ravnovesja pri odraslih.
Following administration of [111In]-radiolabelled Zevalin, whole body scans were performed at up to eight time-points, acquiring both anterior and posterior images.
Po aplikaciji z [111In] označenega zdravila Zevalin so opravili slikanje celega telesa v 8 časovnih razmikih ter naredili posnetke s sprednje in tudi zadnje strani.
Following administration of [14C] temsirolimus, excretion was predominantly via the faeces (78%), with renal elimination of active substance and metabolites accounting for 4.6% of the administered dose.
Po aplikaciji [14C] temsirolimusa se je le-ta izločal iz telesa pretežno z blatom (78 %), 4,6 % danega odmerka zdravilne učinkovine in presnovkov pa se je izločilo preko ledvic.
Following administration of a double dose, reactions are similar in nature to those observed following the administration of a single dose (see section 4.6).
Po dajanju dvojega odmerka so opazili reakcije, podobne po naravi, kot po dajanju enega odmerka (glejte poglavje 4.6).
Following administration of a double dose, reactions are similar in nature to those observed following the administration of a single dose.
Po dajanju dvojega odmerka so opazili reakcije, podobne po naravi kot po dajanju enega odmerka.
Following administration of a radiolabeled oral solution dose to healthy subjects, 93% of the administered dose was recovered in urine and faeces.
Po uporabi odmerka radioizotopsko označene peroralne raztopine pri zdravih preskušancih se je 93 % uporabljenega odmerka odkrilo v urinu in blatu.
Following administration of a single 10 mg/kg dose of telavancin, the pharmacokinetics of telavancin in subjects with moderate hepatic impairment (Child-Pugh class B) were similar to that observed in subjects with normal hepatic function.
Pri dajanju enojnega 10 mg/kg odmerka telavancina, je bila farmakokinetika telavancina pri osebah z zmerno jetrno okvaro (Child–Pugh razred B) podobna tisti, ugotovljeni pri osebah z običajno jetrno funkcijo.
Following administration of a single 1000 mg dose in healthy subjects, an average of 19 % to 33 % of the administered dalbavancin dose was excreted in urine as dalbavancin and 8 % to 12 % as the metabolite hydroxy-dalbavancin.
Po dajanju enega odmerka 1000 mg pri zdravih osebah se je v povprečju od 19 % do 33 % uporabljenega odmerka izločilo z urinom kot dalbavancin in 8 % do 12 % kot presnovek hidroksi-dalbavancin.
Following administration of a single 200 mg IV dose of Sivextro to 8 subjects with severe renal impairment defined as eGFR <30 mL/min, the Cmax was basically unchanged and AUC0-∞ was changed by less than 10% compared to 8 matched healthy subject controls.
Po aplikaciji enkratnega 200 mg intravenskega odmerka zdravila Sivextro 8 preiskovancem s hudo okvaro ledvic, opredeljeno kot eGFR < 30 ml/min, se vrednost Cmax v bistvu ni spremenila, vrednost AUC0-∞ pa se je spremenila za manj kot 10 % v primerjavi z 8 odgovarjajočimi zdravimi preiskovanci iz kontrolne skupine.
Following administration of a single 200 mg oral dose of Sivextro, the pharmacokinetics of tedizolid are not altered in patients with moderate (n=8) or severe (n=8) hepatic impairment (Child-Pugh Class B and C).
Po zaužitju enkratnega 200 mg peroralnega odmerka zdravila Sivextro se farmakokinetika tedizolida pri bolnikih z zmerno (n = 8) ali hudo (n = 8) okvaro jeter (razred B in C po Child-Pughu) ne spremeni.
Following administration of a single 25 mg intravenous dose of temsirolimus in patients with cancer, mean Cmax in whole blood was 585 ng/ml (coefficient of variation [CV] = 14%), and mean AUC in blood was 1627 ng•h/ml (CV = 26%).
Potem ko so bolnikom z rakom dali en 25-miligramski intravenski odmerek temsirolimusa, je bila povprečna Cmax v polni krvi 585 ng/ml (koeficient variacije [CV] = 14 %), povprečna AUC v krvi pa je bila 1627 ngh/ml (CV = 26 %).
Following administration of a single 4 mg/kg or 6 mg/kg intravenous dose of daptomycin over a 30- minute period to subjects with various degrees of renal impairment, total daptomycin clearance (CL) decreased and systemic exposure (AUC) increased as renal function (creatinine clearance) decreased.
Pri dajanju enkratnih 30-minutnih intravenskih odmerkov daptomicina 4 mg/kg ali 6 mg/kg osebam z različnimi stopnjami okvare ledvic se je s slabšanjem ledvične funkcije (zmanjševanjem očistka kreatinina) njihov celotni očistek daptomicina (CL) zmanjševal, sistemska izpostavljenost (AUC) pa povečevala.
Following administration of a single 50 mg-dose, the AUC0- of eltrombopag was 32% to 36% lower in subjects with mild to moderate renal impairment, and 60% lower in subjects with severe renal impairment compared with healthy volunteers.
Pri uporabi enkratnega 50 mg odmerka eltrombopaga je bila pri osebah z blago do zmerno okvaro ledvic vrednost AUC0- eltrombopaga za od 32 % do 36 % manjša kot pri zdravih prostovoljcih, pri osebah s hudo okvaro ledvic pa za 60 % manjša kot pri zdravih prostovoljcih.
Following administration of a single dose of bosutinib (500 mg) with food in healthy subjects, the absolute bioavailability was 34%.
Po zaužitju enkratnega odmerka bosutiniba (500 mg) skupaj s hrano pri zdravih preiskovancih je bila absolutna biološka uporabnost 34%.
Following administration of a single dose of paracetamol 1000 mg, paracetamol AUC and t1/2 were unchanged whatever the timing of its administration (before or after the lixisenatide injection).
Po uporabi enega samega odmerka 1000 mg paracetamola se AUC in t1/2 paracetamola nista spremenila, ne glede na čas uporabe (pred injiciranjem liksisenatida ali po njem).
Following administration of a single oral 0.75 mg dose of [14C]­palonosetron to six healthy subjects, 85% to 93% of the total radioactivity was excreted in urine, and 5% to 8% was eliminated in faeces.
Po dajanju enkratnega peroralnega 0,75 mg odmerka [14C]-palonosetrona šestim zdravim osebam se je 85 % do 93 % celotne radioaktivnost izločilo v urin in 5 % do 8 % v blato.
Following administration of a single oral 750 micrograms dose of [14C]-palonosetron to six healthy subjects, 85 % to 93 % of the total radioactivity was excreted in urine, and 5 % to 8 % was eliminated in feces.
Po dajanju enkratnega peroralnega odmerka 750 mikrogramov 14C-palonosetrona šestim zdravim preiskovancem se je 85 % do 93 % celotne radioaktivnosti odstranilo iz telesa z urinom, 5 % do 8 % pa z blatom.
Following administration of a single oral [14C]canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose was recovered in faeces as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively.
Po odmerjanju enkratnega s [14C] označenega peroralnega odmerka kanagliflozina zdravim osebam so 41,5% danega radioaktivnega odmerka prestregli v blatu v obliki kanagliflozina, 7,0% v obliki hidroksiliranega metabolita in 3,2% v obliki O-glukuronidnega presnovka.
Following administration of a single oral dose of 14C-opicapone, the main excretion route of opicapone and its metabolites was faeces, accounting for 58.5% to 76.8% of the administered radioactivity (mean 67.2%).
Po dajanju enkratnega peroralnega odmerka 14C-opikapona je bila glavna pot izločanja opikapona in njegovih presnovkov blato, kar predstavlja 58,5 % do 76,8 % uporabljene radioaktivnosti (povprečje 67,2 %).
Following administration of a single oral dose of 750 mg 14C-telaprevir in healthy subjects, 90% of total radioactivity was recovered in faeces, urine and expired air within 96 hours post-dose.
Po jemanju enkratnega peroralnega 750 mg odmerka s C14 označenega telaprevirja pri zdravih bolnikih so v blatu, seču in izdihanem zraku izmerili 90% skupne radioaktivnosti v času 96 ur po zaužitju odmerka.
Following administration of a single oral dose of bosutinib 500 mg (therapeutic dose) and bosutinib 500 mg with ketoconazole 400 mg (to achieve supratherapeutic concentrations of bosutinib) in healthy subjects, the upper bound of the one-sided 95% CI around the mean change in QTc was less than 10 ms at all post dose time points, and no AEs suggestive of QTc interval prolongation were observed.
Po uporabi enkratnega peroralnega 500 mg odmerka bosutiniba (terapevtski odmerek) ter 500 mg bosutiniba skupaj s 400 mg ketokonazola (za dosego supraterapevtskih koncentracij bosutiniba) pri zdravih preiskovancih je bila zgornja meja enostranskega 95 % intervala zaupanja okoli povprečne spremembe QTc manj kot 10 ms pri vseh časovnih točkah po odmerku; poleg tega niso opazili neželenih učinkov, ki bi kazali na podaljšanje intervala QTc.
Following administration of abiraterone acetate, the pharmacokinetics of abiraterone and abiraterone acetate have been studied in healthy subjects, patients with metastatic advanced prostate cancer and subjects without cancer with hepatic or renal impairment.
Farmakokinetične lastnosti abiraterona in abirateronacetata po vnosu abirateronacetata so proučevali pri zdravih osebah, pri bolnikih z napredovalim metastatskim rakom prostate in pri osebah brez raka, a z okvaro jeter ali ledvic.
Following administration of an oral [14C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated in faeces (80%) or urine (5%) within 4 days of dosing.
Po dajanju peroralnega odmerka [14C]linagliptina se je pri zdravih preizkušancih približno 85 % radioaktivnosti izločilo z blatom (80 %) ali s sečem (5 %) v 4 dneh po dajanju.
Following administration of an oral [14C]-empagliflozin solution to healthy volunteers, the red blood cell partitioning was approximately 37% and plasma protein binding was 86%.
Po peroralnemu zaužitju raztopine [14C]-empagliflozina je bila pri zdravih prostovoljcih porazdelitev v eritrocite približno 37 %, vezava na beljakovine v plazmi pa 86 %.
Following administration of an oral [14C]sitagliptin dose to healthy subjects, approximately 100 % of the administered radioactivity was eliminated in faeces (13 %) or urine (87 %) within one week of dosing.
Po dajanju peroralnega odmerka [14C]sitagliptina zdravim osebam se je v enem tednu po prejemu odmerka približno 100 % prejete radioaktivnosti izločilo z blatom (13 %) ali urinom (87 %).
Following administration of bazedoxifene alone, a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg and multiple daily doses from 1 mg to 80 mg was observed.
Po uporabi samega bazedoksifena so opazili linearno zvečanje koncentracij v plazmi po enkratnem odmerku od 0,5 mg do 120 mg in večkratnih dnevnih odmerkih od 1 mg do 80 mg.
Following administration of either a single dose of 0.58 mg of Xiapex to 16 patients with Dupuytren’s contracture, or two concurrent injections of 0.58 mg of Xiapex in the same hand in 12 patients with Dupuytren's contracture, no quantifiable levels of Xiapex were detected in plasma from 5 minutes to 30 days post injection.
Po aplikaciji bodisi enkratnega odmerka 0,58 mg zdravila Xiapex 16 bolnikom z Dupuytrenovo kontrakturo ali dveh sočasnih injekcij po 0,58 mg zdravila Xiapex v isto roko 12 bolnikom z Dupuytrenovo kontrakturo v času od 5 minut do 30 dni po injiciranju ni bilo zaznati merljivih nivojev zdravila Xiapex v plazmi.
Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg).
Po dajanju hrane zdravim prostovoljcem so najvišje plazemske koncentracije opazili približno 1 uro po odmerku alafenamidtenofovirata, uporabljenega kot F/TAF (25 mg) ali E/C/F/TAF (10 mg).
Following administration of Nimenrix there is a waning of serum bactericidal antibody titres against group A when using human complement in the assay (hSBA) (see section 5.1).
Pri uporabi preskusa s humanim komplementom (hSBA) so po uporabi cepiva Nimenrix opazili upadanje titrov serumskih baktericidnih protiteles proti skupini A (glejte poglavje 5.1).
Following administration of oral 14C- rivastigmine, renal elimination was rapid and essentially complete (>90%) within 24 hours.
Po zaužitju rivastigmina, označenega s 14C, je bilo ledvično izločanje hitro, saj se je dejansko ves (>90 %) izločil v 24 urah.
Following administration of oral 14C- rivastigmine, renal elimination was rapid and essentially complete (>90%) within 24 hours.
Po zaužitju rivastigmina, označenega s 14C, je bilo ledvično izločanje hitro, saj se je dejansko ves (>90%) izločil v 24 urah.
Following administration of radiolabelled sirolimus, radioactivity is excreted in the milk of lactating rats.
Po dajanju radioaktivno označenega sirolimusa se radioaktivnost pojavi v mleku podganjih samic.
Following administration of SIMBRINZA, small decreases in blood pressure were observed in some patients.
Po uporabi zdravila SIMBRINZA so pri nekaterih bolnikih opazili majhno znižanje krvnega tlaka.
Following administration of single SC doses of 0.1-0.75 mg/kg, plasma concentrations of desirudin increased rapidly to maximum levels (Cmax) between 1 and 3 h.
Po uporabi posamičnih subkutanih odmerkov od 0,1 do 0,75 mg/kg se koncentracija desirudina v plazmi hitro zviša do najvišje ravni (Cmax) v času od 1 do 3 ur.
Following administration of tenofovir alafenamide, plasma [14C] -radioactivity showed a time-dependent profile, with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.
Po dajanju alafenamidtenofovirata je plazemska [14C]-radioaktivnost pokazala časovno odvisni profil, pri tem je bil alafenamidtenofovirat najbolj zastopana vrsta radioaktivnosti v prvih nekaj urah in sečna kislina v preostalem obdobju.
Following administration of tenofovir alafenamide, plasma [14C]-radioactivity showed a time-dependent profile with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.
Po dajanju alafenamidtenofovirata je plazemska [14C]-radioaktivnost pokazala od časa odvisni profil, pre tem je bil alafenamidtenofovirat najbolj zastopana vrsta radioaktivnosti v prvih nekaj urah in sečna kislina v preostalem obdobju.
Following administration of tenofovir alafenamide, plasma [14C]-radioactivity showed a time-dependent profile with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.
Po dajanju alafenamidtenofovirata je plazemska [14C]-radioaktivnost pokazala od časa odvisni profil, pri tem je bil alafenamidtenofovirat najbolj zastopana vrsta radioaktivnosti v prvih nekaj urah in sečna kislina v preostalem obdobju.